MGEN Miragen Therapeutics Inc.

0.99
-0.16  -14%
Previous Close 1.15
Open 1.1
Price To Book 1.94
Market Cap 52,387,342
Shares 53,077,348
Volume 3,678,290
Short Ratio
Av. Daily Volume 881,382
Stock charts supplied by TradingView

NewsSee all news

  1. miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference

    BOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced

  2. miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update

    New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020Additional NIH grant funding released in support of MRG-229 for

  3. miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020

    BOULDER, Colo., April 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today

  4. miRagen Reports Fourth Quarter and Full Year 2019 Financial Results

    Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned enrollment of the Phase 1 trial of cobomarsen in ATLL patients;

  5. miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020

    BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data released October 16, 2019.
MRG-110
Healthy volunteers
Phase 1 data noted median survival time of 26 months compared with 7.4 months in historical cohort and PFS of 12.5 months compared with 5.4 months in historical cohort - January 30, 2020.
Cobomarsen MRG-106
Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Cutaneous T-cell Lymphoma (CTCL); Adult T-Cell Leukemia/Lymphoma (ATLL)
Phase 2 interim data released December 11, 2019 - generally safe and well tolerated. Trial to continue through to primary endpoint.
MRG-201 Remlarsen
Keloids
Phase 2 data delayed due to COVID-19. Initial guidance was for 3Q 2020.
Cobomarsen - SOLAR
Cutaneous T-Cell Lymphoma

Latest News

  1. miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference

    BOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced

  2. miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update

    New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020Additional NIH grant funding released in support of MRG-229 for

  3. miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020

    BOULDER, Colo., April 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today

  4. miRagen Reports Fourth Quarter and Full Year 2019 Financial Results

    Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned enrollment of the Phase 1 trial of cobomarsen in ATLL patients;

  5. miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020

    BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced

  6. miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

    BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced

  7. miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

    BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced

  8. miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

    Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort- - - Median progression free survival

  9. miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences

    BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs,

  10. miRagen Announces Major Changes to Company's Strategy

    Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting in Q2 2020Focusing

  11. miRagen to Present at the Evercore ISI HealthCONx Conference 2019

    BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs,

  12. miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

    Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented restructuring to focus

  13. miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

    An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage